secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-03-06T23:59:59+00:00
Accession:  0000950170-24-026878
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum expects NDA resubmission for oral sulopenem in Q2 2024; cash runway into 2025
--------------------------------------------------------------------------------

- NDA resubmission for oral sulopenem to FDA expected in first half of Q2 2024, earlier than originally planned.
- FDA action expected six months after resubmission (first half of Q4 2024), assuming deficiencies addressed.
- Cash and equivalents as of Dec 31, 2023 plus ATM proceeds through Feb 29, 2024 expected to fund ops into 2025, including through PDUFA date.
- Company plans to engage financial advisor to assist with strategic alternatives (sale, license, or disposal of rights to sulopenem).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024026878/0000950170-24-026878-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024026878/itrm-20240306.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-026878

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer